This section contains links to papers and other resources related to antibody use in the treatment and vaccine development for Ebola Virus Disease.
Neutralizing antibodies for Kikwit strain (1999): Ebola virus can be effectively neutralized by antibody produced in natural human infection [PDF]
Humanized mAbs (ZMapp) expressed in tobacconists (2014): Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp [PDF]
mAbs (MB-003) cocktail (2012): Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques
EBOV IgG+ sera from asymptomatic individuals and symptomatic Gabonese survivors (2014): Identification of continuous human B-cell epitopes in the VP35, VP40, nucleoprotein and glycoprotein of Ebola virus [PDF]
Mouse mAb binding sites mapped to seven antigenic regions, two highly conserved, across all known Ebolavirus species (2013): Mapping of conserved and species-specific antibody epitopes on the Ebola virus nucleoprotein [PDF]
Literature links from Reported functional EBOV-related B cell epitopes (Table 2) on the Immune Epitope Database and Analysis Resource (IEDB) website:
- (2012) Structural basis for differential neutralization of ebolaviruses
- (2011) Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies
- (2008) Complex of a protective antibody with its Ebola virus GP peptide epitope: unusual features of a V lambda x light chain
- (2008) Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor
- (2003) Identification of protective epitopes on ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses
- (2000) Epitopes involved in antibody-mediated protection from Ebola virus
Additional references and detail for above are in our working spreadsheet below.